Skip to content

DrugPatentWatch - Transform Data into Market Domination

Business Intelligence on Biologic and Small Molecule Drugs

Blog Home
DrugPatentWatch Home
Pricing
About
Contact

DrugPatentWatch - Transform Data into Market Domination

Business Intelligence on Biologic and Small Molecule Drugs

Blog Home
DrugPatentWatch Home
Pricing
About
Contact

February 2021

The Global Biosimilar Regulatory Playbook: FDA, EMA, IP Valuation, and the $136 Billion Market Restructuring

The biosimilar market is not a niche concern for generic drug manufacturers. It is the central mechanism by which payors, […]

The Global Biosimilar Regulatory Playbook: FDA, EMA, IP Valuation, and the $136 Billion Market Restructuring Read Post »

DrugPatentWatch featured in Inc Magazine

DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited

DrugPatentWatch featured in Inc Magazine Read Post »

Make Better Decisions

See Plans & Pricing

Recent Posts

Australia’s Drug Patent Clock: The Complete Guide to How Long Protection Actually Lasts
The Reformulation Playbook: How Pharma Uses 505(b)(2) to Lock In New Patents, Block Generics, and Reset Prices
The Drug Patent Cliff: A Procurement Manager’s Sourcing Playbook
Patent Expiration Data: The Procurement Playbook That Cuts Your Drug Spend by 80%
The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Imperil Sponsor Patents

Popular Posts

China’s Irreplaceable Role in the Global Generic Drug API Supply Chain (2026 Report)
First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants
Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification
The Russian Pharmaceutical Industry: A Definitive Guide to Strategic Evolution, Geopolitical Realities, and Market Sovereignty
Double Your Specialty Pharmacy Margins the Day Generics Launch
A Definitive Guide to Valuing Pharmaceutical and Biotech Companies
Branded Generics and Why They’re Profitable
The Reformulation Playbook: How Pharma Uses 505(b)(2) to Lock In New Patents, Block Generics, and Reset Prices
Pharma Licensing Deals: The Complete IP, Valuation, and Deal Structure Playbook
Valuation of Pharmaceutical Companies: A Comprehensive Analysis of Key Considerations

Copyright © 2026 DrugPatentWatch - Transform Data into Market Domination

DrugPatentWatch - Transform Data into Market Domination

Subscribe to Free Updates

3,000+ other biopharma execs get our Drug Patent Expiration Alerts. You should too!

Get fresh news and insights, drug patent expirations & more…

EmailEnter your email address